Article Sidebar

Journal of the international Child Neurology Association Issue 2019
Submitted
February 18, 2018
Accepted
July 21, 2019
Published
November 18, 2019
Download
PDF XML HTML
Statistic
Read Counter : 1725 Download : 1098

Downloads

Download data is not yet available.

Main Article Content

Abstract

Introduction: Congenital cytomegalovirus (CMV) infection is the most common viral infection transmitted via the placenta, causing significant neurodevelopmental impairment in infants and children. Gancyclovir and Valgancyclovir are two drugs used in the treatment of symptomatic CMV infected case which have limited comparative study. This study compared the efficacy and tolerability of these two drugs on symptomatic CMV infected infants.
Methodology: This was an open-label randomized controlled trial done to compare oral valganciclovir(VGCV) with injectable ganciclovir (GCV) in the treatment of symptomatic congenital CMV infected infants. A total of 72 patients were included; 12 patients discontinued the treatment due to noncompliance or side effects. Pre and post-treatment CMV virus levels and adverse effects were monitored. Psychological, visual, and hearing assessments were performed at baseline and six months post-treatment.
Results: The mean age of the infants in VGCV and GCV group was 7.10±3.58 and 7.50±3.99 months, respectively. Nineteen infants presented with developmental delay, 13 with seizure, 4 with a movement disorder. Twenty-one percent of the infants were preterm, and 38% were low birth weight. Eighteen infants had a neonatal seizure. Twenty-eight infants of VGCV and 24 infants of the GCV group showed clearance of the virus after six weeks of treatment. No statistical difference was found in virus clearance. Regarding ophthalmological assessment, infants had chorioretinitis, optic atrophy, squint, and cortical blindness. On hearing assessment, none of the infants deteriorated after drug administration, while some showed improved hearing. None of the infants showed deterioration of cognition, while some of the infants showed
improvement in cognitive assessment, but there was no significant difference in two groups. The side effects of GCV were significantly greater than VGCV (P<0.05). Conclusion: In symptomatic congenital CMV infection in infants, VGCV is as efficient as GCV, and the former has fewer side effects.

Keywords

Cytomegalovirus Ganciclovir Valganciclovir Randomised Controlled Trial

Article Details

License

Copyright (c) 2019 Jannatara Shefa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Author Biographies

Kanij Fatema, Department of Paediatric Neurology, Institute of Pediatric Neurodisorder and Autism (IPNA), Bangabandhu Sheikh Mujib Medical University

Kanij Fatema. FCPS (Pediatric Neurology and Development), FCPS (Pediatrics). Associate Professor, Department of Pediatric Neurology, Institute of Pediatric Neurodisorder and Autism (IPNA), Bangabandhu Sheikh Mujib Medical University.

Md Mizanur Rahman, Department of Paediatric Neurology, Institute of Pediatric Neurodisorder and Autism (IPNA), Bangabandhu Sheikh Mujib Medical University

Md Mizanur Rahman.  FCPS (Pediatrics). Chairman and Professor, Department of Pediatric Neurology, Institute of Pediatric Neurodisorder and Autism (IPNA), Bangabandhu Sheikh Mujib Medical University.

Shaheen Akhtar, Department of Paediatric Neurology, Institute of Pediatric Neurodisorder and Autism (IPNA), Bangabandhu Sheikh Mujib Medical University

Shaheen Akhter.  MD (Pediatrics), Professor, Department of Pediatric Neurology, Institute of Pediatric Neurodisorder and Autism (IPNA), Bangabandhu Sheikh Mujib Medical University. 

Jannatara Shefa, Institute of Paediatric Neurodisorder & Autism (IPNA), Bangabandhu Sheikh Mujib Medical University (BSMMU)

Jannatara Shefa, Ph.D.,  Research Medical Officer, Institute of  Paediatric Neurodisorder anf Autism (IPNA), Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. Email: shefaanaam@gmail.com, Mob: +8801715254283  

How to Cite
Fatema, K., Rahman, M. M., Akhtar, S., & Shefa, J. (2019). Efficacy of Valganciclovir versus Ganciclovir in treatment of symptomatic cytomegalovirus infection in infants: An open-label randomized controlled trial. Journal of the International Child Neurology Association, 1(1). https://doi.org/10.17724/jicna.2019.133
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Albanna, E. A. E., El-Latif, R. S. A., Sharaf, H. A., Gohar, M. K., & Ibrahim, B. M. (2013). Diagnosis of congenital cytomegalovirus infection in high risk neonates. Mediterranean Journal of Hematology and Infectious Diseases, 5(1), e2013049. https://doi.org/10.4084/MJHID.2013.049
  2. Amir, J., Wolf, D. G., & Levy, I. (2010). Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. European Journal of Pediatrics, 169(9), 1061–1067. https://doi.org/10.1007/s00431-010-1176-9
  3. Bialas, K. M., Swamy, G. K., & Permar, S. R. (2015). Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment. Clinics in Perinatology, 42(1), 61–75, viii. https://doi.org/10.1016/j.clp.2014.10.006
  4. Biron, K. K. (2006). Antiviral drugs for cytomegalovirus diseases. Antiviral Research, 71(2–3), 154–163. https://doi.org/10.1016/j.antiviral.2006.05.002
  5. Boppana, S. B., Fowler, K. B., Pass, R. F., Rivera, L. B., Bradford, R. D., Lakeman, F. D., & Britt, W. J. (2005). Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. The Journal of Pediatrics, 146(6), 817–823. https://doi.org/10.1016/j.jpeds.2005.01.059
  6. Boppana, S. B., Ross, S. A., & Fowler, K. B. (2013). Congenital cytomegalovirus infection: clinical outcome. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 57 Suppl 4, S178-81. https://doi.org/10.1093/cid/cit629
  7. Buonsenso, D., Serranti, D., Gargiullo, L., Ceccarelli, M., Ranno, O., & Valentini, P. (2012). Congenital cytomegalovirus infection: current strategies and future perspectives. European Review for Medical and Pharmacological Sciences, 16(7), 919–935. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22953641
  8. Busca, A., de Fabritiis, P., Ghisetti, V., Allice, T., Mirabile, M., Gentile, G., … Falda, M. (2007). Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transplant Infectious Disease : An Official Journal of the Transplantation Society, 9(2), 102–107. https://doi.org/10.1111/j.1399-3062.2006.00183.x
  9. Cheeran, M. C.-J., Lokensgard, J. R., & Schleiss, M. R. (2009). Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clinical Microbiology Reviews, 22(1), 99–126, Table of Contents. https://doi.org/10.1128/CMR.00023-08
  10. Crowley, B. (2002). Ganciclovir treatment of symptomatic congenital cytomegalovirus infection. The Journal of Antimicrobial Chemotherapy, 50(3), 435–436; author reply 436. https://doi.org/10.1093/jac/dkf144
  11. Dahle, A. J., Fowler, K. B., Wright, J. D., Boppana, S. B., Britt, W. J., & Pass, R. F. (2000). Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. Journal of the American Academy of Audiology, 11(5), 283–290.
  12. Foulon, I., Naessens, A., Foulon, W., Casteels, A., & Gordts, F. (2008). A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. The Journal of Pediatrics, 153(1), 84–88. https://doi.org/10.1016/j.jpeds.2007.12.049
  13. Griffiths, P. D. (2002). The 2001 Garrod lecture. The treatment of cytomegalovirus infection. The Journal of Antimicrobial Chemotherapy, 49(2), 243–253. https://doi.org/10.1093/jac/49.2.243
  14. James, S. H., & Kimberlin, D. W. (2016). Advances in the prevention and treatment of congenital cytomegalovirus infection. Current Opinion in Pediatrics, 28(1), 81–85. https://doi.org/10.1097/MOP.0000000000000305
  15. Kimberlin, D. W. (2002). Antiviral therapy for cytomegalovirus infections in pediatric patients. Seminars in Pediatric Infectious Diseases, 13(1), 22–30. https://doi.org/10.1053/spid.2002.29754
  16. Kimberlin, D. W., Acosta, E. P., Sánchez, P. J., Sood, S., Agrawal, V., Homans, J., … National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. (2008). Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. The Journal of Infectious Diseases, 197(6), 836–845. https://doi.org/10.1086/528376
  17. Kimberlin, D. W., Jester, P. M., Sánchez, P. J., Ahmed, A., Arav-Boger, R., Michaels, M. G., … National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. (2015). Valganciclovir for symptomatic congenital cytomegalovirus disease. The New England Journal of Medicine, 372(10), 933–943. https://doi.org/10.1056/NEJMoa1404599
  18. Leung, A. K. C., Sauve, R. S., & Davies, H. D. (2003). Congenital cytomegalovirus infection. Journal of the National Medical Association, 95(3), 213–218. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12749681
  19. Kimberlin, D. W., Lin, C.-Y., Sánchez, P. J., Demmler, G. J., Dankner, W., Shelton, M., … National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. (2003). Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. The Journal of Pediatrics, 143(1), 16–25. https://doi.org/10.1016/s0022-3476(03)00192-6
  20. Lombardi, G., Garofoli, F., Villani, P., Tizzoni, M., Angelini, M., Cusato, M., … Stronati, M. (2009). Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 28(12), 1465–1470. https://doi.org/10.1007/s10096-009-0806-5
  21. Macy, K., Staal, W., Kraper, C., Steiner, A., Spencer, T. D., Kruse, L., … Scahill, L. D. (2013). Bayley Scales of Infants Development-II. In Encyclopedia of Autism Spectrum Disorders (pp. 399–400). https://doi.org/10.1007/978-1-4419-1698-3_284
  22. Mahbub, M., Azam, M., & Khan, N. Z. (2012). Neurodevelopmental Outcome of Treatment of Symptomatic CMV Infection with Ganciclovir. Bangladesh Journal of Child Health, 35(3), 97–101. https://doi.org/10.3329/bjch.v35i3.10498
  23. McDonald, J. M., Raghuveer, T. S., & D’Alessandro, M. P. (2001). Can congenital CMV infection lead to intracranial hemorrhage? Journal of Perinatology : Official Journal of the California Perinatal Association, 21(6), 402–404. https://doi.org/10.1038/sj.jp.7200516
  24. Miura, C. S., Miura, E., Mombach, A. B., & Cheskya, M. (2006). Prevalência de infecção congênita por citomegalovírus em recém-nascidos de uma unidade de tratamento intensivo de um hospital público. Jornal de Pediatria, 82(1). https://doi.org/10.1590/S0021-75572006000100010
  25. Morgan, M. A., El-Ghany, el-S. M. A., Khalifa, N. A., Sherif, A., & Rasslan, L. R. A. (2003). Prevalence of cytomegalovirus (CMV) infection among neonatal intensive care unit (NICU) and healthcare workers. The Egyptian Journal of Immunology, 10(2), 1–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15719606
  26. Muller, W. J. (2017). Treatment of perinatal viral infections to improve neurologic outcomes. Pediatric Research, 81(1–2), 162–169. https://doi.org/10.1038/pr.2016.191
  27. Naing, Z. W., Scott, G. M., Shand, A., Hamilton, S. T., van Zuylen, W. J., Basha, J., … Rawlinson, W. D. (2016). Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention. The Australian & New Zealand Journal of Obstetrics & Gynaecology, 56(1), 9–18. https://doi.org/10.1111/ajo.12408
  28. Nassetta, L., Kimberlin, D., & Whitley, R. (2009). Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. The Journal of Antimicrobial Chemotherapy, 63(5), 862–867. https://doi.org/10.1093/jac/dkp083
  29. Numazaki, K., & Fujikama, T. (2004). Chronological changes of incidence and prognosis of children with asymptomatic congenital cytomegalovirus infection in Sapporo, Japan. BMC Infectious Diseases, 4, 1–5. https://doi.org/10.1186/1471-2334-4-22
  30. Nyholm, J. L., & Schleiss, M. R. (2010). Prevention of maternal cytomegalovirus infection: current status and future prospects. International Journal of Women’s Health, 2, 23–35. https://doi.org/10.2147/ijwh.s5782
  31. Oliver, S. E., Cloud, G. A., Sánchez, P. J., Demmler, G. J., Dankner, W., Shelton, M., … National Institute of Allergy, I. D. C. A. S. G. (2009). Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology, 46 Suppl 4, S22-6. https://doi.org/10.1016/j.jcv.2009.08.012
  32. Ornoy, A., & Diav-Citrin, O. (2006). Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reproductive Toxicology (Elmsford, N.Y.), 21(4), 399–409. https://doi.org/10.1016/j.reprotox.2005.02.002
  33. Pass, R. F. (2002). Cytomegalovirus Infection. Pediatrics in Review, 23(5), 163–170. https://doi.org/10.1542/pir.23-5-163
  34. Pearl, K. N., Preece, P. M., Ades, A., & Peckham, C. S. (1986). Neurodevelopmental assessment after congenital cytomegalovirus infection. Archives of Disease in Childhood, 61(4), 323–326. https://doi.org/10.1136/adc.61.4.323
  35. Plosa, E. J., Esbenshade, J. C., Fuller, M. P., & Weitkamp, J.-H. (2012). Cytomegalovirus Infection. Pediatrics in Review, 33(4), 156–163. https://doi.org/10.1542/pir.33-4-156
  36. Prober, C. G., & Enright, A. M. (2003). Congenital cytomegalovirus (CMV) infections: hats off to Alabama. The Journal of Pediatrics, 143(1), 4–6. https://doi.org/10.1016/S0022-3476(03)00290-7
  37. Rivera, L. B., Boppana, S. B., Fowler, K. B., Britt, W. J., Stagno, S., & Pass, R. F. (2002). Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics, 110(4), 762–767. https://doi.org/10.1542/peds.110.4.762
  38. Shoji, K., Ito, N., Ito, Y., Inoue, N., Adachi, S., Fujimaru, T., … Saitoh, A. (2010). Is a 6-Week Course of Ganciclovir Therapy Effective for Chorioretinitis in Infants with Congenital Cytomegalovirus Infection? The Journal of Pediatrics, 157(2), 331–333. https://doi.org/10.1016/j.jpeds.2010.02.020
  39. SPSS Inc. (n.d.). SPSS for Windows, Version 16.0. Chicago: SPSS Inc.
  40. Sullivan, V., Talarico, C. L., Stanat, S. C., Davis, M., Coen, D. M., & Biron, K. K. (1992). A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature, 358(6382), 162–164. https://doi.org/10.1038/358162a0
  41. Trang, J. M., Kidd, L., Gruber, W., Storch, G., Demmler, G., Jacobs, R., … Stagno, S. (1993). Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clinical Pharmacology and Therapeutics, 53(1), 15–21. https://doi.org/10.1038/clpt.1993.4
  42. van Zuylen, W. J., Hamilton, S. T., Naing, Z., Hall, B., Shand, A., & Rawlinson, W. D. (2014). Congenital cytomegalovirus infection: Clinical presentation, epidemiology, diagnosis and prevention. Obstetric Medicine, 7(4), 140–146. https://doi.org/10.1177/1753495X14552719
  43. Walter, S., Atkinson, C., Sharland, M., Rice, P., Raglan, E., Emery, V. C., & Griffiths, P. D. (2008). Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Archives of Disease in Childhood. Fetal and Neonatal Edition, 93(4), F280-5. https://doi.org/10.1136/adc.2007.119230
  44. Whitley, R. J., Cloud, G., Gruber, W., Storch, G. A., Demmler, G. J., Jacobs, R. F., … Sommadossi, J. P. (1997). Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. The Journal of Infectious Diseases, 175(5), 1080–1086. https://doi.org/10.1086/516445
  45. Wiltshire, H., Paya, C. V, Pescovitz, M. D., Humar, A., Dominguez, E., Washburn, K., … Valganciclovir Solid Organ Transplant Study Group. (2005). Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation, 79(11), 1477–1483. https://doi.org/10.1097/01.tp.0000164512.99703.ad
  46. Yamamoto, A. Y., Mussi-Pinhata, M. M., Cristina, P., Pinto, G., Moraes Figueiredo, L. T., & Jorge, S. M. (2001). Congenital cytomegalovirus infection in preterm and full-term newborn infants from a population with a high seroprevalence rate. The Pediatric Infectious Disease Journal, 20(2), 188–192. https://doi.org/10.1097/00006454-200102000-00014
  47. Yoshinaga-Itano, C., Sedey, A. L., Coulter, D. K., & Mehl, A. L. (1998). Language of early- and later-identified children with hearing loss. Pediatrics, 102(5), 1161–1171. https://doi.org/10.1542/peds.102.5.1161
  48. Zhou, X. J., Gruber, W., Demmler, G., Jacobs, R., Reuman, P., Adler, S., … Sommadossi, J. P. (1996). Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Antimicrobial Agents and Chemotherapy, 40(9), 2202–2205. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8878608

Similar Articles

<< < 1 2 3 4 > >> 

You may also start an advanced similarity search for this article.